Literature DB >> 34342696

Diagnostic and Prognostic Value of Cardiovascular Magnetic Resonance in Neuromuscular Cardiomyopathies.

Batool Almogheer1, Alexios S Antonopoulos1,2, Alessia Azzu1,3, Safaa Al Mohdar1, Charalambos Vlachopoulos2, Antonios Pantazis4, Raad H Mohiaddin5,6.   

Abstract

Neuromuscular diseases (NMD) encompass a broad spectrum of diseases with variable type of cardiac involvement and there is lack of clinical data on Cardiovascular Magnetic Resonance (CMR) phenotypes or even prognostic value of CMR in NMD. We explored the diagnostic and prognostic value of CMR in NMD-related cardiomyopathies. The study included retrospective analysis of a cohort of 111 patients with various forms of NMD; mitochondrial: n = 14, Friedreich's ataxia (FA): n = 27, myotonic dystrophy: n = 27, Becker/Duchenne's muscular dystrophy (BMD/DMD): n = 15, Duchenne's carriers: n = 6, other: n = 22. Biventricular volumes and function and myocardial late gadolinium enhancement (LGE) pattern and extent were assessed by CMR. Patients were followed-up for the composite clinical endpoint of death, heart failure development or need for permanent pacemaker/intracardiac defibrillator. The major NMD subtypes, i.e. FA, mitochondrial, BMD/DMD, and myotonic dystrophy had significant differences in the incidence of LGE (56%, 21%, 62% & 30% respectively, chi2 = 9.86, p = 0.042) and type of cardiomyopathy phenotype (chi2 = 13.8, p = 0.008), extent/pattern (p = 0.006) and progression rate of LGE (p = 0.006). In survival analysis the composite clinical endpoint differed significantly between NMD subtypes (p = 0.031), while the subgroup with LGE + and LVEF < 50% had the worst prognosis (Log-rank p = 0.0034). We present data from a unique cohort of NMD patients and provide evidence on the incidence, patterns, and the prognostic value of LGE in NMD-related cardiomyopathy. LGE is variably present in NMD subtypes and correlates with LV remodelling, dysfunction, and clinical outcomes in patients with NMD.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiovascular magnetic resonance; Fibrosis; Gadolinium; Myopathy; Neuromuscular disease

Mesh:

Substances:

Year:  2021        PMID: 34342696     DOI: 10.1007/s00246-021-02686-y

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  5 in total

1.  Exercise-induced spastic coronary artery occlusion at the site of a moderate stenosis: neither Prinzmetal's angina nor cardiac syndrome X but "Prinzmetal X".

Authors:  Ali Yilmaz; Stephan Hill; Tim Schäufele; Matthias Vöhringer; Angela Geissler; Udo Sechtem
Journal:  Circulation       Date:  2010-12-07       Impact factor: 29.690

2.  Comprehensive Cardiac Magnetic Resonance for Assessment of Cardiac Involvement in Myotonic Muscular Dystrophy Type 1 and 2 Without Known Cardiovascular Disease.

Authors:  Julian A Luetkens; Christina von Landenberg; Alexander Isaak; Anton Faron; Daniel Kuetting; Carla Gliem; Darius Dabir; Cornelia Kornblum; Daniel Thomas
Journal:  Circ Cardiovasc Imaging       Date:  2019-05-29       Impact factor: 7.792

3.  The shape of our hearts: The impact of early stages in life on cardiac development.

Authors:  Chrysovalantou Nikolaidou; Theodoros Karamitsos
Journal:  Eur J Prev Cardiol       Date:  2019-08-13       Impact factor: 7.804

4.  Eosinophilic heart disease: diagnostic and prognostic assessment by cardiac magnetic resonance.

Authors:  Alexios S Antonopoulos; Alessia Azzu; Emmanuel Androulakis; Chonthicha Tanking; Panagiotis Papagkikas; Raad H Mohiaddin
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-01-12       Impact factor: 6.875

5.  Myocardial fibrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic resonance study.

Authors:  Helle Petri; Kiril Aleksov Ahtarovski; Niels Vejlstrup; John Vissing; Nanna Witting; Lars Køber; Henning Bundgaard
Journal:  J Cardiovasc Magn Reson       Date:  2014-08-01       Impact factor: 5.364

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.